Key Players
Competitive Landscape
Competition in trichoderma metabolites spans four business types that control different steps from active development to farm sales. Cell-free developers compete on batch identity and potency because crop trials require a repeatable active before claims can be supported. Large crop-protection groups bring laboratory capacity and production scale for formal approval programs across several crop systems. Buyers compare active quality, technical support and route-to-market strength before selecting a supplier for commercial use.
Farm networks can become a competitive advantage when new biological actives need local trial support and dealer guidance. In June 2025, Koppert signed a five-year agreement for Amoéba's lysate biofungicide across 18 European countries and the United States. The agreement gave AXPERA an established commercial route across several farm markets without changing the product's approval requirements. In March 2026, BASF completed its AgBiTech purchase and added virus-based insect control to its broader crop-protection business. The purchase strengthened BASF's biological portfolio without establishing a public sales-share lead in this exact category.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| In April 2026, Olmix obtained PFC7 certification for Seamel PREVENT. | EU buyers need documented conformity before broad biostimulant distribution. | Certification is becoming a commercial filter for non-microbial plant biostimulants. | Certified crop-specific claims can widen distributor listings for vineyards and orchards. |
| In February 2026, Syngenta expanded Quillibrium distribution to Mexico, Canada and the United States. | Growers need another disease-control option that can fit integrated programs. | Botanical actives are moving from regional use into multi-country distribution. | Local registration and distributor support can extend biological fungicide revenue in the Americas. |
| In September 2025, Borregaard opened a larger Mumbai office with three specialized laboratories. | Formulators need local testing support for plant nutrition and crop-input materials. | Material suppliers are placing application laboratories closer to regional customers. | South Asian formulation work can shorten trials for bio-based dispersants and nutrient products. |
Amoéba and Koppert contribute cell-free or live-fungus crop-care capabilities beyond the three developments mapped below. Seipasa, Acadian Plant Health and BASF SE add plant-response products or fermentation capabilities within the broader competitive set.
Source: Future Market Insights, Trichoderma Metabolites Market Report, 2026-2036.
These firms span active discovery and crop care, with supporting roles in plant-response products and bio-based formulation work across farm channels.
Which companies combine biological active development with broader production capabilities?
Public sources do not provide a reliable sales-share ranking for this exact product category. Amoéba offers a cell-free crop-active route while Syngenta and BASF SE provide broader R&D and production scale.
Which companies hold documented approvals or quality marks for crop biologicals?
Amoéba currently holds crop-protection approval for its AXPERA biofungicide within the current evidence set. Acadian Plant Health and Olmix Group hold current EU marks for named biostimulant products.
Which companies provide crop-protection or plant-response biological products across channels?
Amoéba, Syngenta, BASF SE, Koppert and Seipasa sell or develop crop-protection bio-inputs across established farm channels. Acadian Plant Health and Olmix Group focus on products that support plant response in crop programs.
Which companies currently serve both European and North American crop channels?
Amoéba reaches European and North American farm channels through documented commercial partnerships in both regions. Syngenta, BASF SE, Koppert and Seipasa maintain crop channels across both regions through broader distribution networks.
Representative Company Overview
| Company | Positioning | Verified Direct Evidence |
|---|---|---|
| Amoéba | Cell-free lysate biofungicide developer with European crop-protection commercialization partners. | In May 2026, Amoéba and Koppert received two Dutch permits for large-scale AXPERA trials on food and ornamental crops. |
| Syngenta | Global agricultural biologicals developer with fermentation and multi-region crop channels. | In February 2025, Syngenta announced start-up of its first world-scale U.S. agricultural biologicals facility in Orangeburg. |
| BASF SE | Global crop-protection company adding fermentation and biological active manufacturing. | In May 2026, BASF commissioned its BioHub fermentation plant in Ludwigshafen for biological crop-protection actives. |
| Koppert | Biological crop-protection firm with Trichoderma-based biofungicides and global farm support. | In July 2026, Koppert published lettuce trial results for Trianum that documented soil-borne disease control and harvestable-yield effects. |
| Seipasa | Biopesticide and biostimulant developer with international registration and distribution routes. | In February 2026, Seipasa launched Basei Mg as a natural foliar solution with fungicidal action. |
| Acadian Plant Health | Seaweed-based biostimulant developer with formulation and regulatory programs for broad-acre crops. | In August 2025, Acadian added its fifth CE-marked biostimulant under the EU Fertilising Products Regulation. |
| Olmix Group | Seaweed-derived plant-care developer serving crop nutrition and biostimulant applications. | In May 2025, Olmix reported HZPC validation of its Algomel foliar biosolutions in seed potato programs. |
| Borregaard ASA | Bio-based formulation material producer supporting agricultural dispersants and crop-protection development. | In June 2025, Borregaard launched the CROPSAFE project to develop bio-based pest-control options for food crops. |
Research Methodology
FMI selected firms that represent the main competitive roles across active development and crop-input commercialization. Each company requires current evidence of cell-free actives or crop bio-inputs with a documented route to commercial sales. Natural plant products and formulation materials qualify only when public evidence shows a direct role in the defined product field. Official approvals and company announcements support each dated development used within this competitive addendum. Public filings and certifications define current business scope, while every claim remains tied to the named product and crop route. FMI keeps sales-share estimates as proprietary forecast work because public sources do not rank this exact category.
